Literature DB >> 11992260

A comprehensive mutation analysis of RP2 and RPGR in a North American cohort of families with X-linked retinitis pigmentosa.

Debra K Breuer1, Beverly M Yashar, Elena Filippova, Suja Hiriyanna, Robert H Lyons, Alan J Mears, Bersabell Asaye, Ceren Acar, Raf Vervoort, Alan F Wright, Maria A Musarella, Patricia Wheeler, Ian MacDonald, Alessandro Iannaccone, David Birch, Dennis R Hoffman, Gerald A Fishman, John R Heckenlively, Samuel G Jacobson, Paul A Sieving, Anand Swaroop.   

Abstract

X-linked retinitis pigmentosa (XLRP) is a clinically and genetically heterogeneous degenerative disease of the retina. At least five loci have been mapped for XLRP; of these, RP2 and RP3 account for 10%-20% and 70%-90% of genetically identifiable disease, respectively. However, mutations in the respective genes, RP2 and RPGR, were detected in only 10% and 20% of families with XLRP. Mutations in an alternatively spliced RPGR exon, ORF15, have recently been shown to account for 60% of XLRP in a European cohort of 47 families. We have performed, in a North American cohort of 234 families with RP, a comprehensive screen of the RP2 and RPGR (including ORF15) genes and their 5' upstream regions. Of these families, 91 (39%) show definitive X-linked inheritance, an additional 88 (38%) reveal a pattern consistent with X-linked disease, and the remaining 55 (23%) are simplex male patients with RP who had an early onset and/or severe disease. In agreement with the previous studies, we show that mutations in the RP2 gene and in the original 19 RPGR exons are detected in <10% and approximately 20% of XLRP probands, respectively. Our studies have revealed RPGR-ORF15 mutations in an additional 30% of 91 well-documented families with X-linked recessive inheritance and in 22% of the total 234 probands analyzed. We suggest that mutations in an as-yet-uncharacterized RPGR exon(s), intronic changes, or another gene in the region might be responsible for the disease in the remainder of this North American cohort. We also discuss the implications of our studies for genetic diagnosis, genotype-phenotype correlations, and gene-based therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992260      PMCID: PMC379141          DOI: 10.1086/340848

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  47 in total

1.  Isolation of retinal proteins that interact with retinitis pigmentosa GTPase regulator by interaction trap screen in yeast.

Authors:  R Roepman; D Schick; P A Ferreira
Journal:  Methods Enzymol       Date:  2000       Impact factor: 1.600

Review 2.  Gene therapy for ocular disease.

Authors:  J Bennett; A M Maguire
Journal:  Mol Ther       Date:  2000-06       Impact factor: 11.454

3.  Mutations in the N-terminus of the X-linked retinitis pigmentosa protein RP2 interfere with the normal targeting of the protein to the plasma membrane.

Authors:  J P Chapple; A J Hardcastle; C Grayson; L A Spackman; K R Willison; M E Cheetham
Journal:  Hum Mol Genet       Date:  2000-08-12       Impact factor: 6.150

4.  Mutation detection in the breast cancer gene BRCA1 using the protein truncation test.

Authors:  W Moore; I Bogdarina; U A Patel; M Perry; C Crane-Robinson
Journal:  Mol Biotechnol       Date:  2000-02       Impact factor: 2.695

5.  X-linked retinitis pigmentosa: mutation spectrum of the RPGR and RP2 genes and correlation with visual function.

Authors:  D Sharon; G A Bruns; T L McGee; M A Sandberg; E L Berson; T P Dryja
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-08       Impact factor: 4.799

6.  Identification of a novel protein interacting with RPGR.

Authors:  J P Boylan; A F Wright
Journal:  Hum Mol Genet       Date:  2000-09-01       Impact factor: 6.150

7.  Evidence for a new locus for X-linked retinitis pigmentosa (RP23).

Authors:  A J Hardcastle; D L Thiselton; I Zito; N Ebenezer; T S Mah; M B Gorin; S S Bhattacharya
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-07       Impact factor: 4.799

Review 8.  Genetic testing for familial adenomatous polyposis.

Authors:  W G Ballhausen
Journal:  Ann N Y Acad Sci       Date:  2000-06       Impact factor: 5.691

9.  Mutational hot spot within a new RPGR exon in X-linked retinitis pigmentosa.

Authors:  R Vervoort; A Lennon; A C Bird; B Tulloch; R Axton; M G Miano; A Meindl; T Meitinger; A Ciccodicola; A F Wright
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

10.  A retinitis pigmentosa GTPase regulator (RPGR)-deficient mouse model for X-linked retinitis pigmentosa (RP3).

Authors:  D H Hong; B S Pawlyk; J Shang; M A Sandberg; E L Berson; T Li
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  106 in total

1.  In-frame deletion in a novel centrosomal/ciliary protein CEP290/NPHP6 perturbs its interaction with RPGR and results in early-onset retinal degeneration in the rd16 mouse.

Authors:  Bo Chang; Hemant Khanna; Norman Hawes; David Jimeno; Shirley He; Concepcion Lillo; Sunil K Parapuram; Hong Cheng; Alison Scott; Ron E Hurd; John A Sayer; Edgar A Otto; Massimo Attanasio; John F O'Toole; Genglin Jin; Chengchao Shou; Friedhelm Hildebrandt; David S Williams; John R Heckenlively; Anand Swaroop
Journal:  Hum Mol Genet       Date:  2006-04-21       Impact factor: 6.150

2.  Transcriptional profile analysis of RPGRORF15 frameshift mutation identifies novel genes associated with retinal degeneration.

Authors:  Sem Genini; Barbara Zangerl; Julianna Slavik; Gregory M Acland; William A Beltran; Gustavo D Aguirre
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-23       Impact factor: 4.799

3.  Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa.

Authors:  William A Beltran; Artur V Cideciyan; Alfred S Lewin; Simone Iwabe; Hemant Khanna; Alexander Sumaroka; Vince A Chiodo; Diego S Fajardo; Alejandro J Román; Wen-Tao Deng; Malgorzata Swider; Tomas S Alemán; Sanford L Boye; Sem Genini; Anand Swaroop; William W Hauswirth; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

4.  The retinitis pigmentosa protein RP2 interacts with polycystin 2 and regulates cilia-mediated vertebrate development.

Authors:  Toby Hurd; Weibin Zhou; Paul Jenkins; Chia-Jen Liu; Anand Swaroop; Hemant Khanna; Jeffrey Martens; Friedhelm Hildebrandt; Ben Margolis
Journal:  Hum Mol Genet       Date:  2010-08-20       Impact factor: 6.150

5.  PDE6D binds to the C-terminus of RPGR in a prenylation-dependent manner.

Authors:  Je-Jung Lee; Seongjin Seo
Journal:  EMBO Rep       Date:  2015-11-09       Impact factor: 8.807

Review 6.  Insights into X-linked retinitis pigmentosa type 3, allied diseases and underlying pathomechanisms.

Authors:  Paulo A Ferreira
Journal:  Hum Mol Genet       Date:  2005-10-15       Impact factor: 6.150

7.  Loss of retinitis pigmentosa 2 (RP2) protein affects cone photoreceptor sensory cilium elongation in mice.

Authors:  Linjing Li; Kollu Nageswara Rao; Yun Zheng-Le; Toby W Hurd; Concepción Lillo; Hemant Khanna
Journal:  Cytoskeleton (Hoboken)       Date:  2015-10-14

8.  Organization on the plasma membrane of the retinitis pigmentosa protein RP2: investigation of association with detergent-resistant membranes and polarized sorting.

Authors:  J Paul Chapple; Celene Grayson; Alison J Hardcastle; Tracey A Bailey; Karl Matter; Peter Adamson; Catriona H Graham; Keith R Willison; Michael E Cheetham
Journal:  Biochem J       Date:  2003-06-01       Impact factor: 3.857

9.  Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial.

Authors:  Dennis R Hoffman; Dianna K Hughbanks-Wheaton; N Shirlene Pearson; Gary E Fish; Rand Spencer; Alison Takacs; Martin Klein; Kirsten G Locke; David G Birch
Journal:  JAMA Ophthalmol       Date:  2014-07       Impact factor: 7.389

10.  Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations.

Authors:  William A Beltran; Artur V Cideciyan; Shannon E Boye; Guo-Jie Ye; Simone Iwabe; Valerie L Dufour; Luis Felipe Marinho; Malgorzata Swider; Mychajlo S Kosyk; Jin Sha; Sanford L Boye; James J Peterson; C Douglas Witherspoon; John J Alexander; Gui-Shuang Ying; Mark S Shearman; Jeffrey D Chulay; William W Hauswirth; Paul D Gamlin; Samuel G Jacobson; Gustavo D Aguirre
Journal:  Mol Ther       Date:  2017-05-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.